The German pharma will license a KRAS G12D inhibitor from Kumquat Biosciences. Elsewhere, a Biohaven OCD drug missed its ...

Germany’s Bayer and privately-held Kumquat Biosciences, a US biotech founded by pioneers of the KRAS pathway, have entered into an exclusive global license and collaboration to develop and ...

Today’s White House MAHA Commission report is expected to pull punches on pesticide regulation as Bayer lobbies to limit ...

German pharmaceutical giant Bayer said Tuesday it had struck a deal valued at up to $1.3 billion (1.1 billion euros) with a US ...